Avonex label change
Executive Summary
FDA approves revised labeling for Biogen's Avonex Nov. 12 indicating a lower occurrence of neutralizing antibodies to Avonex than previously demonstrated in Phase III trials. The revised label places the rate of occurrence of neutralizing antibodies at 5% (13 of 261 patients), down from 24%, based on changes in Avonex' manufacturing process. Labeling for Serono's Rebif carries a 24% rate of neutralizing antibodies, although labeling for both products notes that the clinical significance of neutralizing antibodies is unknown, and that rates cannot be compared...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.